Web App Tracks Side Effects in Patients With Large B-Cell Lymphoma
Tests a web app for reporting side effects in adults starting first-line treatment for lymphoma.
Plain-language title generated from the registry record
Registry title: Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma
Key facts
- Where
- Bordeaux, Le Mans, Nantes, Saint-Nazaire, and Strasbourg, FranceSee the 5 sites
Where in France
- Polyclinique Bordeaux Nord AquitaineBordeaux, FranceNo longer taking part
- Clinique Victor Hugo/Centre Jean Bernard/ILCLe Mans, FranceNo longer taking part
- Hôpital Privée du ConfluentNantes, FranceNo longer taking part
- Centre Hospitalier de St NazaireSaint-Nazaire, FranceNo longer taking part
- Centre de radiothérapie de RobertsauStrasbourg, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Weprom
- Trial code
- NCT05298293
- Record updated
- 5 April 2022
- Original description
Diffuse large B cell lymphoma is the most common malignant lymphoid hemopathy. More than half of the patients will be cured with an RCHOP-type immunochemotherapy protocol (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone). Monitoring of adverse effects, risk of relapse and quality of life are essential in overall management. Patients are the best candidates to report them. Managing these events should improve quality of life and reduce costs. The aim of this study is to assess the feasibility of monitoring these events by a web application (Oncolaxy©) and to compare it with a control population in the context of a randomized pilot study including 80 patients per arm with diffuse large cell B lymphoma in first-line treatment with R-CHOP.Read full original descriptionShow less
Evaluation of a Web Application on Event Reporting for Patients With B Lymphoma on First Line Treatment
Diffuse large B cell lymphoma is the most common malignant lymphoid hemopathy. More than half of the patients will be cured with an RCHOP-type immunochemotherapy protocol (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone). Monitoring of adverse effects, risk of relapse and quality of life are essential in overall management. Patients are the best candidates to report them. Managing these events should improve quality of life and reduce costs. The aim of this study is to assess the feasibility of monitoring these events by a web application (Oncolaxy©) and to compare it with a control population in the context of a randomized pilot study including 80 patients per arm with diffuse large cell B lymphoma in first-line treatment with R-CHOP.
Inclusion: Patient with untreated large B cell lymphoma requiring a first line treatment by RCHOP or R-mini-CHOP; Patient aged 18 years or older at the time of signing Informed Consent Form; Additional Intrathecal or/and intravenous treatment with Methotrexate allowed, if indicated; Eastern Cooperative Oncology Group (ECOG) Performance Status < 3; Patient with internet access (or has someone at home who can help send patients' symptoms or complete the form); Patient enrolled in social security; Patient has given his written consent ahead of any specific protocol procedure.
Exclusion: Patient is being treated for another cancer and has not been cured; Patient with dementia, mental disorders or psychological pathology which could compromise patient informed consent and/or the observance of the study protocol; Patient with symptomatic brain metastases,; Patient deprived of their liberty, under guardianship or trusteeship; Patient cannot submit to the protocol for psychological, social, familial or geographical reasons; Patient is pregnant or breastfeeding.